Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine

Yihao Liu^{1,2,3#}, Qin Zeng^{4#}, Caiguanxi Deng^{3#}, Mengyuan Li^{4#}, Liubing Li^{5#}, Dayue Liu^{6#}, Ming Liu³, Xinyuan Ruan⁴, Jie Mei², Ruohui Mo², Qian Zhou², Min Liu⁵, Sui Peng^{2,3}, Ji Wang^{3*}, Hui Zhang^{3,4*}, Haipeng Xiao^{1*}

¹Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People's Republic of China

²Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People's Republic of China

³Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People's Republic of China

⁴Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People's Republic of China

⁵Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People's Republic of China

⁶Department of Medical Affairs, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, People's Republic of China

Running title: third dose of inactivated SARS-CoV-2 vaccine.

#These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 *Co-correspondent authors

24 *Lead contact:

25 Haipeng Xiao, MD, PhD

26 Professor of Medicine in Endocrinology

27 President of the First Affiliated Hospital of Sun Yat-sen University

28 58 ZhongShan Second Road, Guangzhou, 510080, P. R. China.

29 Tel: +86-136-0976-3571

30 E-mail: xiaohp@mail.sysu.edu.cn

31

Abstract:

SARS-CoV-2 inactivated vaccines have shown remarkable efficacy in clinical trials, especially in reducing severe illness and casualty. However, the waning of humoral immunity over time has raised concern over the durability of immune memory following vaccination. Thus, we conducted a non-randomized trial among the healthcare professionals (HCWs) to investigate the long-term sustainability of SARS-CoV-2-specific B cells and T cells stimulated by inactivated vaccines and the potential need for a third booster dose. Although neutralizing antibodies elicited by the standard two-dose vaccination schedule dropped from a peak of 29.3 AU/ml to 8.8 AU/ml 5 months after the second vaccination, spike-specific memory B and T cells were still detectable, forming the basis for a quick recall response. As expected, the faded humoral immune response was vigorously elevated to 63.6 AU/ml by 7.2 folds 1 week after the third dose along with abundant spike-specific circulating follicular helper T cells in parallel. Meanwhile, spike-specific CD4⁺ and CD8⁺ T cells were also robustly elevated by 5.9 and 2.7 folds respectively. Robust expansion of memory pools by the third dose potentiated greater durability of protective immune responses. Another key finding in this trial was that HCWs with low serological response to 2 doses were not truly “non-responders” but fully equipped with immune memory that could be quickly recalled by a third dose even 5 months after the second vaccination. Collectively, these data provide insights into the generation of long-term immunological memory by the

54 inactivated vaccine, which could be rapidly recalled and further boosted by a
55 third dose.

56

57 **Key words:** SARS-CoV-2, inactivated vaccine, immunological memory,
58 SARS-CoV-2-specific memory B cells, SARS-CoV-2-specific memory T cells,
59 booster dose

60

Introduction

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread across the globe currently^{1, 2}. The pandemic has brought profound casualties of human lives and socioeconomic issues. The establishment of herd immunity by vaccination represents the most cost-effective strategy to prevent COVID-19. The rapid spreading of COVID-19 has urged the governments to authorize the emergent use of vaccines against SARS-CoV-2³⁻⁵.

The presence of neutralizing antibodies (NAbs) against SARS-CoV-2 is an indicator of protective immunity after vaccination or infection^{6, 7}. NAbs capable of blocking the interaction between the spike protein and its receptor angiotensin converting enzyme 2 (ACE2) are particularly important for protection from COVID-19⁸. Therefore, inducing potent NAbs and long-lasting memory B cells are the primary goal of SARS-CoV-2 vaccines. Two doses of mRNA or inactivated vaccines are capable of inducing potent neutralizing antibody responses^{9,3, 10}. Our previous study further demonstrated that inactivated vaccines elicited SARS-CoV-2 specific memory B cells¹¹, which are important for a rapid and robust recall of protective responses against viral infection. However, little is known how long can these immune responses sustain. A rapid decline of neutralizing antibodies has been observed among infected healthcare workers (HCWs)¹². Neutralizing antibodies also waned

overtime after the second dose of BNT162b2 or ChAdOx1¹³, indicating weakened protection for SARS-CoV-2 infection. In addition, the rapid emergence of novel SARS-CoV-2 variants of concern (VOCs) dampens the efficacy of SARS-CoV-2 vaccines, since vaccine-induced antibodies were less effective in neutralizing some emerging VOCs¹⁴. Moreover, cross-reactive antibodies against VOCs decayed even faster than antibodies against wild-type strain¹⁵.

Besides humoral immune responses, T cells also play a pivotal role in coordinating the adaptive immune responses and as effectors against viral infection. In some cases, patients with inherited or treatment-induced B cell deficiency were able to recover from COVID-19^{16, 17}, suggesting a potential role of cellular responses in fighting against SARS-CoV-2 infection. Induction of CD8⁺ T cell responses was documented in both SARS-CoV-2 infection and vaccination^{18, 19}. On the other hand, rapid induction of CD4⁺ T cells is associated with coordinated humoral and cellular response to a SARS-CoV-2 mRNA vaccine²⁰. SARS-CoV-2 specific circulating T follicular helper cells (cTFH) cells, whose counterparts in lymph nodes reinforce B cells and humoral responses²¹, correlated with neutralizing antibody levels in convalescent COVID-19 patients^{22, 23}.

Nevertheless, T cell responses induced by inactivated vaccines are much less

well characterized than humoral immunity. One previous study revealed that the inactivated vaccine could elicit T cells response after 2 doses of vaccination²⁴, but the phenotype and sustainability of antigen-specific CD4⁺ and CD8⁺ T cells remained unclear yet.

In this study, we sought to investigate the sustainability of immune memory stimulated by the inactivated vaccine and profile humoral and cellular responses to a third dose among HCWs. Although NAbs declined substantially, SARS-CoV-2-specific memory B, CD4⁺, and CD8⁺ T cells persisted in the peripheral blood 5 months after the second vaccination, even in participants who were seronegative after receiving 2 doses of the inactivated vaccines. The third vaccination robustly recalled both humoral and cellular immune responses in all participants.

Materials and methods

Human subjects

In this study, we conducted a non-randomized trial and recruited participants from a prospective cohort at the First Affiliated Hospital of Sun Yat-sen University (FAH-SYSU) in Guangzhou, China. As we described previously¹¹, 63 HCWs received the inactivated SARS-CoV-2 vaccine BBIBP-CorV (BBIBP-CorV, Sinopharm, Beijing) in the morning (9 am – 11 am) or afternoon (3 pm – 5 pm) on day (d) 0 and d28, respectively. Fifty of the 63 HCWs were

volunteered to receive a third booster shot of the inactivated vaccine 6 months after the prime vaccination (d180). They were assigned to the morning or afternoon group as to their previous vaccinating time accordingly. Demographic characteristics of the HCWs were summarized in Supplementary Table 1. Blood samples were collected on d180 before the booster dose and d187, d194 and d208 after the booster dose. Convalescent patients who had recovered from SARS-CoV-2 infection were recruited as the positive control (Supplementary Table 2). All studies were approved by the Institutional Review Board of FAH-SYSU and written consent was obtained from all participants. The prospective cohort and the trial were registered to Chinese Clinical Trial Registry (ChiCTR2100042222 and ChiCTR2100048665).

Cell isolation

Blood samples were collected into the heparinized tubes and processed right after sample collection. Peripheral blood mononuclear cells (PBMCs) were isolated using density-gradient centrifugation. Briefly, blood samples were diluted with PBS at 1:1 ratio and loaded on top of Lymphoprep™ (StemCell) in the Falcon tubes. The falcon tubes were then centrifuged at 1500 rpm for 30 mins. The medium layer was collected and washed with PBS twice. PBMCs were cryopreserved in Bambanker (StemCell) immediately.

SARS-CoV-2 neutralizing antibodies measurement

A one-step competitive Chemiluminescent immunoassay was used to detect the concentration of NAbS against SARS-CoV-2 in sera by iFlash 2019-nCoV NAb kit (YHLO Biotech Co, Ltd) as previously reported²⁵. In this assay, receptor binding domain (RBD) of the SARS-CoV-2 was coated on magnetic beads. Acridinium ester-labeled ACE2 was designed to compete with SARS-CoV-2 NAbS in sera for the RBD. NAb titers were calculated by an iFlash3000 Chemiluminescence Immunoassay Analyzer (YHLO Biotech Co, Ltd). Neutralizing activity is determined in arbitrary units (AU) and the cut-off is 10 AU/ml.

Ex vivo ELISpot assay

IFN γ ELISpot assays were performed as described previously²⁶. Briefly, 100 μ l of the coating antibody (15 μ g/ml, MabTech, #3420-3-250) was added to the well of ELISpot plate (MabTech) and incubated overnight at 4°C. The peptide pool of SARS-CoV-2 spike protein (MabTech, #3630-1) was added to 300,000 PBMCs per test at a final concentration of 2 μ g/ml for 24 h. Unstimulated cells were used as negative control while anti-CD3/CD28 dynabeads (Thermo Fisher) stimulated cells were set as the positive control. Plates were incubated with IFN γ detection antibody (1 μ g/ml, MabTech, #3420-6-250), followed by Avidin-HRP (1 μ g/ml, Vector, #A-2004-5) and visualized using the ACE substrate. Antigen-specific T cell responses were quantified by subtracting the number of spots in unstimulated cells from the peptide stimulated cells.

SARS-CoV-2-specific B cell ELISpot was performed as previously described²⁷. Briefly, ELISpot plates were coated with 10 ug/ml recombinant RBD protein (Sino Biological, #40592-VNAH-100) and 8 ug/ml spike protein (Sino Biological, #40589-V08B1) overnight at 4°C. To optimize the human IgG B cell ELISpot assay, PBMCs were cultured with a mixture of R848 (1 µg/ml, Tocris, #4536/10) and IL-2 (20 ng/ml, PeproTech, #200-02-10) for 3 days to secrete a detectable amount of antibody^{28, 29}. After pre-stimulation, cells were washed extensively to remove secreted antibodies. 500,000 PBMCs were added to the coated plates and incubated for 18 h at 37°C with 5% CO₂. The following day, cells were removed and plates were incubated with Biotin-anti-Human IgG (1µg/ml, Jackson ImmunoResearch, #709-065-098). Plates were then incubated with Avidin-HRP followed by visualization with ACE substrate. ELISpot plates were analyzed using an ELISpot counter (Cellular Technologies Ltd). Results were expressed as spot-forming units (s.f.u.) per 10⁶ PBMCs. Responses were considered positive if the results were at least three times the mean of the negative control wells and >25 s.f.u. per 10⁶ PBMCs. Data were excluded when negative control wells had >30 s.f.u. per 10⁶ PBMCs or positive control wells (anti-CD3/CD28 dynabeads) had no spot.

Activation-induced markers (AIM) T cell assay.

PBMCs were cultured in RPMI 1640 supplemented with 10% FBS and 1%

penicillin and streptomycin (Thermo Fisher) at 37 °C overnight. The cells were then cultured with or without the peptide pool of SARS-CoV-2 spike protein (2 µg/ml) for 12 h. An equal concentration of DMSO in PBS was used as the negative control. Antigen-specific T cells were measured as a percentage of AIM⁺ (OX40⁺CD137⁺) for CD4⁺ T or (CD69⁺CD137⁺) for CD8⁺ T cells after stimulation of PBMCs with the peptide pool of spike protein²⁶. After the stimulation, cells were first stained with Zombie Red for dead cell exclusion. Cells were then stained with anti-CD3-Pacific blue, anti-CD4-BV510, anti-CD8-Percp, anti-CD69-Super Bright 436, anti-CD134 (OX40)-BV605 and anti-CD137-(4-1BB)-PE antibodies for antigen-specific T cell analysis. As for phenotype analysis of SARS-CoV-2-specific T cells, cells were further labeled with anti-CCR7-APC/cy7, anti-CD45RA-BV650, anti-CXCR5-BV711 and anti-PD-1-PE/cy7 antibodies. All FACS antibodies were from Biolegend. Stimulation with anti-CD3/CD28 dynabeads was included as positive controls. Any sample with a low response to anti-CD3/CD28 stimulation was excluded as quality control for the samples. Data were acquired by flow cytometry.

Detection of SARS-CoV-2-specific memory B cells

SARS-CoV-2-specific memory B cells were detected as we described previously¹¹. First, biotinylated antigens were multimerized with fluorescence-labeled streptavidin individually. Recombinant spike protein (R&D, #BT10549-050) was mixed with BV510-streptavidin (BioLegend) at 10:1

ratio and BV785-streptavidin (BioLegend) at 18:1 ratio at 4°C for 1h. Recombinant RBD protein (R&D, #BT10500-050) was mixed with BV421-streptavidin (BioLegend) at 20:1 ratio at 4°C for 1h. The antigen probes prepared above were then mixed in 50mM free d-biotin (Macklin) in PBS to ensure minimal cross-reactivity. PBMCs were thawed and let to rest at 37°C with 5% CO₂ for 2h and stained with Zombie Red (BioLegend) in PBS at room temperature for 20 min. Cells were then stained with 50 µl of antigen probe cocktail containing 100 ng of spike and 50 ng of RBD at 4°C for 30 min. Cells were washed with PBS and then stained with the following antibody cocktail: anti-CD3-Pacific Blue™, anti-CD19-PE-CY7, anti-CD27-AF700, anti-IgD-FITC, anti-CD38-BV650, anti-IgM-BV605, anti-IgG-AF647, anti-IgA-PE all from BioLegend at 1:100 dilution. Samples were acquired by flow cytometry.

Detection of SARS-CoV-2-specific IFN γ -producing T cells

The detection of spike-reactive T cells was performed as described with modification³⁰. Briefly, overnight-rested PBMCs were cultured with or without the peptide pool of SARS-CoV-2 spike protein (4 µg/ml) in the presence of 3 µg/ml of anti-CD28 monoclonal antibodies for 24 h. Cells were then incubated with Brefeldin A for additional 5 h. Cells were stained with anti-CD3-Pacific blue, anti-CD4-BV510, anti-CD8-Percp antibodies for surface markers. Cells were then washed, fixed with Cytofix/Cytoperm and stained with anti-IFN γ -PE-Cy7 (BioLegend). Dead cells were excluded by Zombie Red

staining. Samples were analyzed by flow cytometry. Samples without peptide stimulation were used as the negative control.

Flow cytometry

All flow cytometry samples were analyzed using cryopreserved cells which were thawed and suspended in RPMI 1640 media supplemented with 2% FBS. All samples were analyzed by flow cytometry with Cytex™ AURORA. FlowJo (Tree Star, USA) software was used for FACS data analysis. Details of antibodies used in this study are listed in Supplementary Table 3.

ELISA-based antibody-antigen distribution analysis

All SARS-CoV-2 proteins were purchased from Sino Biological (Beijing, China). 200ng/well of SARS-CoV-2 spike (40589-V08B1), spike S1 subunit (40591-V08H), spike NTD (40591-V49H), spike S2 subunit (40590-V08B), RBD (40592-V08H), RBD T478K (40592-V08H91), nucleocapsid (40588-V08B) and envelope (40609-V10E3) were coated on the 96-well ELISA plate overnight at 4 °C, respectively. Plates were washed by PBS supplemented with 0.05% Tween-20 (PBST) three times, followed by blocking with 5% BSA in PBST for 1 h at room temperature. Sera were diluted 20-fold for the first well and 4-fold serial diluted for subsequent wells in 5% BSA in PBST, and incubated at 4°C overnight. Plates were washed 3 times by PBST, and added with HRP-conjugated goat anti-human IgG antibody (2040-05,

SouthernBiotech, 1:3000) for 30 min at room temperature. Plates were washed five times with PBST. 3,3',5,5'-Tetramethylbenzidine (TMB) substrate (P0209, Beyotime) was added for 15 min, and stopped by the stopping buffer (C1058, Solarbio). OD450 was measured by Varioskan Lux Microplate Reader (Thermo Fisher).

Pseudovirus neutralizing assay

For the generation of SARS-CoV-2-Spike (Wuhan-Hu-1) pseudovirus³¹, pcDNA3.1-2019-nCoV-Spike and pNL4-3 R⁻E⁻ (gifts from Dr. Lu Lu, Fudan University) were co-transfected to HEK293T with Lipo8000 (C0533, Beyotime) according to the manufacturer's instruction. For the generation of the B.1.617.2 Delta-variant spike pseudovirus, pCMV3-SARS-CoV-2-Spike (VG40804-UT, Sino Biological), pSPAX2 and pLenti-CMV-Luc-puro were co-transfected to HEK293T. The virus was harvested 72 hours post-transfection and stored at -80°C until use. 2x10⁴ hACE2-293T/well were seeded on the black flat-bottom 96-well plate (655090, Greiner Bio-one) for 16 hours in advance. Sera were diluted 10-fold for the first well and 4-fold serial diluted for subsequent wells in DMEM, then co-incubated with pseudovirus at 37°C for 1 hour. Then the co-incubated samples, together with samples without sera or pseudovirus as controls, were subjected with 10µg/ml polybrene (C0351, Beyotime) to the hACE2-293T for 6-hour absorption, following by replacement of the culture medium for the next 42 hours

incubation at 37°C, 5% CO₂. Infected cells were processed to the luciferase assay using the Luciferase Assay System (E4550, Promega). The luminescence was measured by Varioskan Lux Microplate Reader (Thermo Fisher). The 50% pseudovirus neutralization titer (pNT50) were determined by four-parameter nonlinear regression curve (GraphPad Prism).

Statistical analysis

Statistical analysis was performed using Prism 5.0. Comparisons were assessed using Wilcoxon rank sum test, Student's t-test, paired Student's t-test or One-way ANOVA followed by Bonferroni's multiple comparison post-test as appropriate. P values < 0.05 were considered as statistically significant.

Results

Neutralizing antibody response is enhanced by a third dose of inactivated SARS-CoV-2 vaccine BBIBP-CorV.

We have previously conducted a non-randomized trial and recruited HCWs from a prospective cohort, demonstrating the impact of the circadian rhythm on the immune response induced by a primary 2-dose series of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV, Sinopharm, Beijing)¹¹. Fifty HCWs from this cohort were volunteered to participate in the current non-randomized trial to investigate the duration of the primary vaccination regimen and potential benefits of a third dose, given 5 months after the second dose (Fig. 1A). No

severe side effects related to vaccination were recorded during the trial (Supplementary Table 1).

Blood samples were collected from multiple time points before and after each dose and NAbs targeting RBD were measured by Chemiluminescent immunoassay²⁵. The mean serum concentration of NAbs dropped by 70% from d56 (1 month post the second dose) to d180, 5 months after the second dose (Fig. 1B). Intriguingly, NAbs maintained a significantly higher level in the morning vaccination group than that in the afternoon group on d180 (Fig. 1D).

Although serum NAbs in 72% of participants (36/50) dropped below the threshold (10 AU/ml) on d180, serological responses could be rapidly recalled to an unprecedented level within 1 week after the third dose. The mean concentration of NAbs was increased by 7.2 folds from 8.8 AU/ml on d180 to 63.6 AU/ml on d187, peaking at 92.3 AU/ml 2 weeks after the booster (Fig. 1C). As the primary vaccination series¹¹, the circadian rhythm also governed the outcome of the third dose, albeit only at the early stage. Significantly higher levels of NAbs were observed in the morning group after the third dose on d187 (Fig. 1D). However, the difference between the morning and the afternoon groups gradually diminished over time (Fig. 1D). Moreover, we did not observe any difference in NAbs levels between females and males (Fig. 1E).

325

326 Pseudovirus neutralizing assays were next applied to confirm the elevation of
327 serum NAbs against wild type (WT) SARS-CoV-2 and VOCs by the third dose.
328 Consistent with the results of Chemiluminescent immunoassay, the 50%
329 pseudovirus neutralization titer (pNT50) against WT was greatly boosted (Fig.
330 1F). Encouragingly, the third dose not only elevated the NAbs against WT, but
331 also strengthen a cross-protective immune response. The mean serum pNT50
332 against B.1.167.2 Delta variant was increased by 10-fold from day180 to
333 day194 (Fig. 1G). In pseudovirus assay, a significantly higher level of NAbs
334 against both WT and B.1.167.2 could still be observed in morning vaccination
335 participants (Fig. 1H and I).

336

337 One potential advantage of inactivated vaccines over other vaccine types is
338 that they comprise all viral structural proteins which may induce a broader
339 spectrum of immunity in addition to NAbs against RBD. To profile the antibody
340 spectrum induced by BBIBP-CorV, serum IgG against major SARS-CoV-2
341 structural proteins and their subdomains, including S1, S2, RBD, NTD of spike
342 protein, nucleocapsid, and small envelope protein, were measured by indirect
343 ELISA before and after the third dose. As expected, BBIBP-CorV successfully
344 elicited antibodies against all structural proteins and subdomains tested
345 (Supplementary Fig. 1). Notably, we found all vaccinees were equipped with a
346 high titer of anti-envelope IgG which has not been reported in a vaccine study

elsewhere and was hardly induced even during natural SARS-CoV-2 infection³². Interestingly, the third dose did not elevate antibody responses against all tested structural proteins or subdomains evenly, but profoundly augment the immune response against the S1 domain of spike protein which comprises NTD and RBD subdomains (Supplementary Fig. 1).

SARS-CoV-2 specific memory B cell response is robustly induced by a third dose of inactivated vaccine

The rapid and robust recall of humoral immune responses by the third vaccination indicated that the primary 2-dose vaccination regimen has established a sustained immune memory. We explored the presence of antigen-specific memory B cells before and after the third dose by flow cytometry.

Total B cell populations were first characterized by flow cytometry (Supplementary Fig. 2). Only mild changes in IgD⁺, IgM⁺, IgA⁺ or IgD⁺CD27⁻ B cells were found before and after the booster, whereas the percentage of total and naïve B cells were not affected (Supplementary Fig. 3), consistent with a good safety profile of the third dose (Supplementary Table. 1).

Next, antigen-specific B cell populations were investigated. Spike- and RBD-specific memory B cells could be detected at 4 weeks (d56) and 5

months (d180) after the second dose, revealing that memory B cells persisted despite a decreasing trend over a 5-months time frame between second and third immunization (Fig. 2A and C). The third dose increased the percentages of spike- and RBD-specific memory B cells by 1.7 and 2.0 folds respectively from d180 to d187, resulting in a significantly larger memory pool on d187 than that on d56 (Fig. 2B and D). The majority of these antigen-specific memory B cells could be classified into IgG⁺ or IgM⁺ B cells, while a minor population of them was IgA⁺ B cells (Fig. 2E and F).

The capability of these Spike- or RBD-specific memory B cells in secreting antibodies upon the antigen stimulation was further confirmed by B cell ELISpot. The third dose boosted spike- or RBD-responsive, IgG-secreting B cells from 8 u.f.c/10⁶ PBMCs to 17 u.f.c/10⁶ PBMCs or 4 u.f.c/10⁶ PBMCs to 10.7 u.f.c/10⁶ PBMCs respectively (Fig. 2G-I). These results demonstrated that the primary 2-dose vaccination regimen had equipped vaccinees with long-lasting memory B cells which could be immediately recalled and further expanded by a third dose of the inactivated vaccine.

The cellular immune response is boosted by a third dose of inactivated SARS-CoV-2 vaccine

Besides humoral immune responses, the cellular arm of immunity confers another layer of protection, which may particularly crucial when B cell epitopes

mutate rapidly and continuously. Therefore, antigen-specific T cells induced by the primary vaccination regimen and the third dose booster were next investigated. Blood samples collected on d180 and d187 were stimulated by the spike peptide pool and IFN γ -secreting cells were quantified by ELISpot. Surprisingly, antigen-responsive IFN γ -secreting T cells were readily detected in all vaccinees even 5 months after the second dose, though a lower amount was found in some participants (Fig. 3A and B). As IgG-secreting B cells, IFN γ -secreting T cell responses were also enhanced by 2.3 folds after the third dose (Fig. 3A and B).

Next, SARS-CoV-2-specific CD8 $^{+}$ were identified by AIM T cell assay, based on the previous observation that antigen-specific CD8 $^{+}$ T cells could be identified by CD69 $^{+}$ 4-1BB $^{+}$ after the peptide pool stimulation²⁶. In line with ELISpot, CD8 $^{+}$ CD69 $^{+}$ 4-1BB $^{+}$ T cells were seen on d180, and further elevated by 2.7 folds following a booster shot (Fig. 3C and D). Subsequent analysis on phenotypic markers revealed that the majority of the SARS-CoV-2-specific CD8 $^{+}$ T cells were CD45RA $^{+}$ CCR7 $^{-}$ terminally differentiated effector memory cells (T_{EMRA}), whereas CD45RA $^{-}$ CCR7 $^{-}$ effector memory T cells (T_{EM}) accounted for only one-fourth of the total antigen-specific CD8 $^{+}$ T cells (Fig. 3E), similar to that from recovered COVID-19 patients²⁶. The subsets of total CD8 $^{+}$ T cells were not affected (Supplementary Fig. 4 and Fig. 5). The presence of antigen-specific CD8 $^{+}$ T cells was further confirmed by

conventional intracellular cytokine staining (ICS) assay, in which PBMCs were stimulated with spike peptide pool and IFN γ expression in CD8 $^{+}$ T cells was measured by flow cytometry. CD8 $^{+}$ IFN γ^{+} T cells were detected on d56, and decreased over time till the third vaccination, which elevated IFN γ -expressing CD8 $^{+}$ T cells to a greater extent when compared to that on d56 (Fig. 3H and I).

SARS-CoV-2-specific CD4 $^{+}$ T cells were identified by activation markers OX40 and 4-1BB after the peptide stimulation²⁶. CD4 $^{+}$ OX40 $^{+}$ 4-1BB $^{+}$ T cells were detected at a low level on d180. The third dose induced the expansion of these CD4 $^{+}$ T cells by 5.9 folds within 1 week (Fig. 4A and B). Phenotypic analysis showed that the majority of the SARS-CoV-2-specific CD4 $^{+}$ T cells were CD45RA $^{-}$ CCR7 $^{+}$ T_{CM} and CD45RA $^{-}$ CCR7 $^{-}$ T_{EM}, different from that of SARS-CoV-2-specific CD8 $^{+}$ T cells (Fig. 4C). Among SARS-CoV-2-specific CD4 $^{+}$ T cells, 57.7% of the cells were CXCR5 $^{+}$ cTFH cells (Fig. 4D-G). Among total CD4 $^{+}$ T cells, we observed the slightly decreased T_N cells, with increased T_{EM} and T_{CM} cells in the peripheral blood (Supplementary Fig. 4 and Fig. 5). Again, SARS-CoV-2-specific CD4 $^{+}$ T cells were confirmed by ICS assay. CD4 $^{+}$ IFN γ^{+} T cells showed a similar trend as that of CD8 $^{+}$ IFN γ^{+} T cells. As expected, the drop of antigen-specific CD4 $^{+}$ T cells was reversed by the third dose (Fig. 4H and I).

Besides CD4 $^{+}$ and CD8 $^{+}$ T cells, we also found a unique population,

SARS-CoV-2-specific CD3⁺CD4⁺CD8⁻ T cells persisted 5 months after the second immunization with inactivated vaccines, which were further elevated by the third vaccination (Fig. 3F and G).

A third dose of inactivated SARS-CoV-2 vaccine boosts immune responses in individuals with negative serologic responses to 2 doses.

The weakened or negative serological response has been noted in a small group of vaccinees who had no known immunodeficiency disease or were not in an immune-compromised condition. It is unclear that whether these people are true “non-responders”, and whether a third dose is necessary and beneficial as in immune-compromised patients^{33, 34}. In this study, we found NABs were below the threshold in 9 participants after the primary 2-dose regimen. Of note, these participants have no known immunodeficiency disease or are not in an immune-compromised condition. The level of NABs in all of the 9 participants increased rapidly within 1 week and reach the peak 2 weeks after the booster shot (Fig. 5A), though NABs levels in these 9 participants were still significantly lower than others who were seropositive after the second dose (Fig. 5B).

The rapid recall of humoral responses indicated that the immune memory had been successfully established in these seronegative people after the second dose and persisted for at least 5 months. As expected, SARS-CoV-2-specific

memory B cells were indeed detected by labeling antigen-binding BCR in these individuals on d56 and d180. The percentage of SARS-CoV-2-specific memory B cells was quite stable over time between d56 and d180, and increased significantly after the third dose (Fig. 5C). ELISpot was next enrolled to identify functional memory B and T cells. Although no NABs were detected at any time point before the third dose, spike- or RBD-specific IgG-secreting memory B cells were able to be detected by ELISpot on d56 and maintained at a similar level till d180. The number increased within 1 week after the third dose and persisted thereafter (Fig. 5D and F).

Spike-specific T cells were also able to be detected on d56 and d180 as measured by ELISpot, albeit with a downward trend (Fig. 5G and H). As expected, the third dose was capable of enhancing T cell responses in this population (Fig. 5H). The enhancement on SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells by the third dose was further confirmed by measuring AIM⁺ T cells (OX40⁺4-1BB⁺ for CD4⁺ T cells and CD69⁺4-1BB⁺ for CD8⁺ T cells) by flow cytometry. Both spike-specific CD4⁺ T cells and CD8⁺ T cells were successfully expanded (Fig. 5I and J). We also observed the expansion of SARS-CoV-2-specific cTFH cells in these participants (Fig. 5K). Taken together, these results suggested that these participants were not true “no responders”, immune memory had been established but repeated antigen stimulations were needed.

479

480 **Discussion**

481 In this study, we investigated the duration of B cell and T cell immunity
 482 following the primary 2-dose vaccination regimen of the inactivated
 483 SARS-CoV-2 vaccine BBIBP-CorV and the potential benefit of a third dose in a
 484 non-randomized trial. Data in this study showed that neutralizing antibodies
 485 gradually decreased after the second dose during a 5-month observation.
 486 SARS-CoV-2-specific B cells and T cells were detected and persisted in the
 487 peripheral blood 5 months after the second vaccination. Both humoral and
 488 cellular responses were rapidly and robustly elevated by a third dose of
 489 inactivated SARS-CoV-2 vaccine. The induction of both SARS-CoV-2-specific
 490 memory B cells and T cells by the inactivated vaccine supports durable
 491 protection, as has been shown in mRNA vaccines and other settings^{35, 36}.
 492 Another key observation in this study was the successful induction of
 493 antigen-specific memory B cell and T cell response in HCWs with low
 494 serological response to 2 doses of inactivation vaccines.

495

496 The NAb titers have been noted to decay following vaccination or SARS-CoV-2
 497 infection³⁷⁻³⁹. However, HCWs who have recovered from COVID-19 show a
 498 substantially lower risk of reinfection with SARS-CoV-2⁴⁰. The number of
 499 RBD-specific memory B cells remained relatively stable between 6 and 12
 500 months after SARS-CoV-2 infection and BCR repertoire expanded markedly in

these recovered patients after receiving an mRNA vaccine⁴¹. Consistently, we found that spike- and RBD-specific memory B cells could still be detected in all COVID-19 convalescent patients up to 13 months after infection (Supplementary Fig. 6). SARS-CoV-2 mRNA vaccines were also capable of inducing sustained immune memory and long-term protecting effects^{35, 42, 43}. Our study, together with these aforementioned studies, suggests that SARS-CoV-2-specific memory B cells may sustain longer than plasma cells. Prediction of vaccine efficacy should not solely rely on NAbs titers. Rather, memory B cells should be taken into account whenever it is possible.

Recently, a third dose of inactivated vaccine CoronaVac elicited a rapid and long-lasting recall antibody response with the capability of neutralizing several VOCs⁴⁴. The rapid and strong secondary response by the inactivated vaccine represents a characteristic secondary immune response, which demonstrates the establishment of long-term immune memory within these participants. Our data confirm that SARS-CoV-2-specific memory B cells persisted 6 months later the primary vaccination and expanded substantially by a third dose of vaccine. The secondary immune response is one of the most important features of immune memory stimulated by vaccination, which is characterized by a faster and stronger immune response by memory B cells or plasma cells⁴⁵. Despite the waning of antibodies, the generation of SARS-CoV-2-specific memory B cells could mediate recall response in future infection and provide

protective immunity. As has been observed in recovered COVID-19 patients, long-lived bone marrow spike-binding plasma cells are quiescent²⁷, which explains the declining antibodies over time. Nonetheless, further investigation should be conducted on how waning immunity could affect protection against COVID-19.

Our data revealed that long-lasting memory B cells formed a basis for an enormous lift of serum NAbs after the third dose, not only against WT SARS-CoV-2 but also against B.1.617.2 Delta variant. As shown in Supplementary Fig.1, the inactivated vaccine induced a broad spectrum of antibody responses to multiple structural proteins of the virus. Whether the lifted cross-reactive NAbs still targeted to RBD, or other domains of S protein, or even other proteins were involved, is an interesting question meriting further study.

Our study showed that SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells in convalescent COVID-19 patients could persist up to 13 months (Supplementary Fig. 7). SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells induced by BBIBP-CorV were detected in all the HCWs who received 2 doses of vaccine and last for at least 5 months. In line with previous data from an mRNA vaccine²⁰, SARS-CoV-2-specific CD4⁺ T cells induced by inactivated vaccine mainly fall into central and effector memory subsets, while the majority of

SARS-CoV-2-specific CD8⁺ T cells were T_{EMRA} cells. Because of the high CCR7 expression, the central memory T cells reside in the secondary lymphoid organs and readily expand upon infection or booster vaccination. Effector memory T cells circulate in between blood and peripheral tissues, providing prompt immune response at the early time point of infection^{46, 47}. For the emergence of VOCs of SARS-CoV-2, there is growing concern over vaccine efficacy. In addition, T cells from COVID-19 convalescents and in recipients of mRNA vaccine could recognize epitopes throughout the SARS-CoV-2 spike protein and the total reactivity against SARS-CoV-2 variants of B.1.1.7, B.1.351, P.1, and CAL.20C lineages were mostly maintained in terms of magnitude and frequency of response⁴⁸. SARS-CoV-2-specific T cells from convalescent COVID-19 patients or vaccinated individuals targeted the conserved epitopes between prototype and VOCs^{49, 50}. Thus, SARS-CoV-2-specific T cells are less likely to be affected by antibody escapes mutations in VOCs. Moreover, the inactivated virus vaccine comprises all viral structural proteins. This means more epitopes, especially those conserved epitopes in proteins other than spike are engaged as compared to mRNA or recombinant protein vaccines involving only RBD or spike. Ideally, a potent adjuvant rather than aluminum salts should be used to fully realize this advantage.

Another interesting finding of this study was the induction of

SARS-CoV-2-specific cTFH cells by the inactivated vaccine. Our previous study has demonstrated the mobilization of cTFH cells after the first dose of inactivated vaccination¹¹. For the relatively late development of humoral response by the inactivated vaccines, early response of cTFH cells could contribute to the early protection of vaccination when antibody level was still low^{3, 51}. cTFH cells have been associated with humoral response in COVID-19 patients or vaccination individuals^{20, 23}. Data in this study further confirmed that the induction of cTFH cells by the inactivated vaccine correlated with humoral response closely.

A third dose of the SARS-CoV-2 vaccine may be particularly in need for the immunocompromised population. Low seroconversion rates to mRNA vaccination have been reported in solid transplant recipients⁵². The applications of immune suppressants or B cell-targeted therapies could also hamper serological response to vaccination^{53, 54}. Recently, data show that antibody response was enhanced in kidney transplant recipients with minimal serologic response to 2 doses by a third dose of mRNA vaccine³³. In this study, we found that a group of healthy individuals was not mounted with detectable NAbs by two doses of vaccination. However, memory B and T cells could be detected 5 months after the second immunization. The third dose of inactivated vaccine could induce an elevated level of NAbs and an extensive expansion of memory cells within 1 week, suggesting that the memory

response could also be effectively recalled upon SARS CoV-2 infection.

Therefore, these individuals were not true “non-responders” but already equipped with immune memory which may at least confer protection against severe diseases. Nevertheless, it should be noted that further studies are needed to confirm the relevance between these memory responses and protection. Moreover, a third dose is necessary to further secure the protection.

In conclusion, our study revealed sustained memory B and T cell responses after a standard 2-dose vaccination regimen of inactivated vaccines. Immune responses against SARS-CoV-2 were readily recalled and further elevated by a third dose of the inactivated vaccine, which is especially beneficial for individuals facing high exposure risks, such as HCWs, and has been demonstrated to be safe and effective in our study and others^{33, 55}.

Author Contributions:

HX, HZ and JW supervised the study. YL, QZeng, CD, MLi, LL and DL contributed equally to the study. HX, HZ, JW and YL conceived and designed the study. YL, DL, JM and RM recruited participants in the trial and collected blood samples. QZeng, CD, ML, MLi and LL performed the experiments and collected data. QZeng and QZhou performed statistical analysis. HZ, YL, QZeng, CD, MLi, LL and DL drafted the report. HX, JW, SP and MLiu made critical revision on the manuscript. All authors contributed to the interpretation

611 of data. All authors approved the final version before submission.

612

613 **Acknowledgment**

614 We thank Prof. Lu Lu at Fudan University for his kind help in pseudovirus

615 assays. The work is supported by The Talent Program of the First Affiliated

616 Hospital, Sun Yat-sen University (Y70311) and The Hundred Talent Program of

617 Sun Yat-sen University (Y61229).

618

619 **Conflict interests:** The authors have no conflicts of interest to disclose.

620

621

Reference:

- 1 Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. *BMJ* 2021; **374**:n1648.
- 2 COVID-19 Map - Johns Hopkins Coronavirus Resource Center. <https://coronavirus.jhu.edu/maphtml> 2021.
- 3 Xia S, Zhang Y, Wang Y *et al.* Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis* 2021; **21**:39-51.
- 4 Jackson LA, Anderson EJ, Rouphael NG *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med* 2020; **383**:1920-1931.
- 5 Krause PR, Gruber MF. Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations. *N Engl J Med* 2020; **383**:e107.
- 6 Khoury DS, Cromer D, Reynaldi A *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021; **27**:1205-1211.
- 7 Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nat Med* 2021; **27**:1147-1148.
- 8 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veasler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020; **181**:281-292 e286.
- 9 Goel RR, Apostolidis SA, Painter MM *et al.* Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following

644 mRNA vaccination. *Sci Immunol* 2021; **6**.

645 10 Xia S, Duan K, Zhang Y *et al*. Effect of an Inactivated Vaccine Against
646 SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2
647 Randomized Clinical Trials. *JAMA* 2020; **324**:951-960.

648 11 Zhang H, Liu Y, Liu D *et al*. Time of day influences immune response to an
649 inactivated vaccine against SARS-CoV-2. *Cell Res* 2021.

650 12 Marot S, Malet I, Leducq V *et al*. Rapid decline of neutralizing antibodies
651 against SARS-CoV-2 among infected healthcare workers. *Nat Commun* 2021;
652 **12**:844.

653 13 Shrotri M, Navaratnam AMD, Nguyen V *et al*. Spike-antibody waning after
654 second dose of BNT162b2 or ChAdOx1. *Lancet* 2021; **398**:385-387.

655 14 Krause PR, Fleming TR, Longini IM *et al*. SARS-CoV-2 Variants and
656 Vaccines. *N Engl J Med* 2021; **385**:179-186.

657 15 Pegu A, O'Connell S, Schmidt SD *et al*. Durability of mRNA-1273
658 vaccine-induced antibodies against SARS-CoV-2 variants. *Science* 2021.

659 16 Soresina A, Moratto D, Chiarini M *et al*. Two X-linked agammaglobulinemia
660 patients develop pneumonia as COVID-19 manifestation but recover. *Pediatr*
661 *Allergy Immunol* 2020; **31**:565-569.

662 17 Wurm H, Attfield K, Iversen AK, Gold R, Fugger L, Haghikia A. Recovery
663 from COVID-19 in a B-cell-depleted multiple sclerosis patient. *Mult Scler* 2020;
664 **26**:1261-1264.

665 18 Oberhardt V, Luxenburger H, Kemming J *et al*. Rapid and stable

666 mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. *Nature* 2021.

667 19 Kared H, Redd AD, Bloch EM *et al.* SARS-CoV-2-specific CD8+ T cell
668 responses in convalescent COVID-19 individuals. *J Clin Invest* 2021; **131**.

669 20 Painter MM, Mathew D, Goel RR *et al.* Rapid induction of antigen-specific
670 CD4(+) T cells is associated with coordinated humoral and cellular immunity to
671 SARS-CoV-2 mRNA vaccination. *Immunity* 2021.

672 21 Crotty S. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol* 2011;
673 **29**:621-663.

674 22 Boppana S, Qin K, Files JK *et al.* SARS-CoV-2-specific circulating T
675 follicular helper cells correlate with neutralizing antibodies and increase during
676 early convalescence. *PLoS Pathog* 2021; **17**:e1009761.

677 23 Juno JA, Tan HX, Lee WS *et al.* Humoral and circulating follicular helper T
678 cell responses in recovered patients with COVID-19. *Nat Med* 2020;
679 **26**:1428-1434.

680 24 Deng Y, Li Y, Yang R, Tan W. SARS-CoV-2-specific T cell immunity to
681 structural proteins in inactivated COVID-19 vaccine recipients. *Cell Mol*
682 *Immunol* 2021; **18**:2040-2041.

683 25 Tenbusch M, Schumacher S, Vogel E *et al.* Heterologous prime-boost
684 vaccination with ChAdOx1 nCoV-19 and BNT162b2. *Lancet Infect Dis* 2021;
685 **21**:1212-1213.

686 26 Dan JM, Mateus J, Kato Y *et al.* Immunological memory to SARS-CoV-2
687 assessed for up to 8 months after infection. *Science* 2021; **371**.

688 27 Turner JS, Kim W, Kalaidina E *et al.* SARS-CoV-2 infection induces
689 long-lived bone marrow plasma cells in humans. *Nature* 2021; **595**:421-425.

690 28 Jahnmatz M, Kesa G, Netterlid E, Buisman AM, Thorstensson R, Ahlborg N.
691 Optimization of a human IgG B-cell ELISpot assay for the analysis of
692 vaccine-induced B-cell responses. *J Immunol Methods* 2013; **391**:50-59.

693 29 Long QX, Jia YJ, Wang X *et al.* Immune memory in convalescent patients
694 with asymptomatic or mild COVID-19. *Cell Discov* 2021; **7**:18.

695 30 Peng Y, Mentzer AJ, Liu G *et al.* Broad and strong memory CD4(+) and
696 CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals
697 following COVID-19. *Nat Immunol* 2020; **21**:1336-1345.

698 31 Xia S, Liu M, Wang C *et al.* Inhibition of SARS-CoV-2 (previously
699 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor
700 targeting its spike protein that harbors a high capacity to mediate membrane
701 fusion. *Cell Res* 2020; **30**:343-355.

702 32 Tea F, Ospina Stella A, Aggarwal A *et al.* SARS-CoV-2 neutralizing
703 antibodies: Longevity, breadth, and evasion by emerging viral variants. *PLoS*
704 *Med* 2021; **18**:e1003656.

705 33 Benotmane I, Gautier G, Perrin P *et al.* Antibody Response After a Third
706 Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant
707 Recipients With Minimal Serologic Response to 2 Doses. *JAMA* 2021.

708 34 Hall VG, Ferreira VH, Ku T *et al.* Randomized Trial of a Third Dose of
709 mRNA-1273 Vaccine in Transplant Recipients. *N Engl J Med* 2021.

- 710 35 Goel RR, Painter MM, Apostolidis SA *et al.* mRNA Vaccination Induces
711 Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants
712 of Concern. *bioRxiv* 2021.
- 713 36 Akondy RS, Fitch M, Edupuganti S *et al.* Origin and differentiation of human
714 memory CD8 T cells after vaccination. *Nature* 2017; **552**:362-367.
- 715 37 Israel A, Shenhar Y, Green I *et al.* Large-scale study of antibody titer decay
716 following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. *medRxiv* 2021.
- 717 38 Long QX, Tang XJ, Shi QL *et al.* Clinical and immunological assessment of
718 asymptomatic SARS-CoV-2 infections. *Nat Med* 2020; **26**:1200-1204.
- 719 39 Ibarondo FJ, Fulcher JA, Goodman-Meza D *et al.* Rapid Decay of
720 Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl J Med*
721 2020; **383**:1085-1087.
- 722 40 Hall VJ, Foulkes S, Charlett A *et al.* SARS-CoV-2 infection rates of
723 antibody-positive compared with antibody-negative health-care workers in
724 England: a large, multicentre, prospective cohort study (SIREN). *Lancet* 2021;
725 **397**:1459-1469.
- 726 41 Wang Z, Muecksch F, Schaefer-Babajew D *et al.* Naturally enhanced
727 neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*
728 2021; **595**:426-431.
- 729 42 Doria-Rose N, Suthar MS, Makowski M *et al.* Antibody Persistence through
730 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *N Engl*
731 *J Med* 2021; **384**:2259-2261.

- 732 43 Tenforde MW, Self WH, Naioti EA *et al.* Sustained Effectiveness of
733 Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated
734 Hospitalizations Among Adults - United States, March-July 2021. *MMWR Morb*
735 *Mortal Wkly Rep* 2021; **70**:1156-1162.
- 736 44 Kang W. ea. A third dose of inactivated vaccine 1 augments the potency,
737 breadth, and duration of anamnestic responses against SARS-CoV-2.
738 *medRxiv* 2021.
- 739 45 Quast I, Tarlinton D. B cell memory: understanding COVID-19. *Immunity*
740 2021; **54**:205-210.
- 741 46 Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation:
742 implications for vaccine development. *Nat Rev Immunol* 2002; **2**:251-262.
- 743 47 Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector
744 memory T cell subsets: function, generation, and maintenance. *Annu Rev*
745 *Immunol* 2004; **22**:745-763.
- 746 48 Tarke A, Sidney J, Methot N *et al.* Impact of SARS-CoV-2 variants on the
747 total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals.
748 *Cell Rep Med* 2021; **2**:100355.
- 749 49 Skelly DT, Harding AC, Gilbert-Jaramillo J *et al.* Two doses of SARS-CoV-2
750 vaccination induce robust immune responses to emerging SARS-CoV-2
751 variants of concern. *Nat Commun* 2021; **12**:5061.
- 752 50 Redd AD, Nardin A, Kared H *et al.* CD8+ T-Cell Responses in COVID-19
753 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent

754 SARS-CoV-2 Circulating Variants. *Open Forum Infect Dis* 2021; **8**:ofab143.

755 51 Al Kaabi N, Zhang Y, Xia S *et al*. Effect of 2 Inactivated SARS-CoV-2
756 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized
757 Clinical Trial. *JAMA* 2021; **326**:35-45.

758 52 Boyarsky BJ, Werbel WA, Avery RK *et al*. Antibody Response to 2-Dose
759 SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.
760 *JAMA* 2021; **325**:2204-2206.

761 53 Haberman RH, Herati R, Simon D *et al*. Methotrexate hampers
762 immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated
763 inflammatory disease. *Ann Rheum Dis* 2021.

764 54 Mrak D, Tobudic S, Koblichke M *et al*. SARS-CoV-2 vaccination in
765 rituximab-treated patients: B cells promote humoral immune responses in the
766 presence of T-cell-mediated immunity. *Ann Rheum Dis* 2021.

767 55 Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three
768 Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *N*
769 *Engl J Med* 2021; **385**:661-662.

770

771

Figures and legends

Figure 1 Humoral responses induced by a third dose of inactivated SARS-CoV-2 vaccine BBIBP-CorV. (A) Protocol of the prospective cohort and the non-randomized trial. Healthcare workers (HCWs) were recruited from a perspective cohort who received two doses of an inactivated vaccine either in the morning (AM, n=25) or afternoon (PM, n=25) on day (d) 0 and d28. They were assigned to morning or afternoon vaccination to receive a third dose of the inactivated vaccine on day 180 according to their previous vaccinating time.

Blood samples were collected on different time points d0 (T1), d14 (T2), d21 (T3), d28 (T4), d56 (T5), d180 (T6), d187 (T7), d194 (T8) and d208 (T9). (B-E) Neutralizing antibodies (NAbs) against SARS-CoV-2 in the serum of each volunteer was measured by Chemifluorescence Assay longitudinally. (B) The concentration of NAbs in the sera at different time points was summarized and shown in the box plot. (C) The longitudinal changes of NAbs in the sera before and after the third dose of vaccination. (D) NAbs in the sera from the morning or afternoon group at different time points. (E) NAbs concentrations in the sera of female or male. Medians of the data were shown. (F, G) Neutralizing activities of sera from T6 and T8 against SARS-CoV-2 wild type (WT) and Delta variant (B.1.167.2) were measured by pseudovirus neutralizing assay. (H, I) Comparison of neutralizing activities between the morning and afternoon group on T8. Data are mean $\pm$ SEM. Comparisons were done by Wilcoxon rank sum test in B, D, E or Student's t-test in F-I. **p<0.01, ****p<0.0001; ns, not significant.

Figure 2 SARS-CoV-2-specific memory B cell after a third dose of inactivated vaccine. Recombinant spike or receptor binding domain (RBD) proteins were used to label SARS-CoV-2-specific BCRs. Data were acquired by flow cytometry. (A, C) Representative FACS plots for spike- or RBD-specific BCR were shown. (B, D) Longitudinal changes of spike- or RBD-specific

804 memory B cells were summarized. (E) IgG⁺, IgA⁺ and IgM⁺ B cells were
 805 measured by flow cytometry. UMAP plot demonstrated the distribution of
 806 spike- and RBD-specific memory B cells in IgG⁺, IgA⁺ and IgM⁺ B cells. (F)
 807 Mean percentages of each BCR subtype in spike- and RBD-specific B cells
 808 were summarized. (G) Spike- or RBD-specific IgG-secreting B cells were
 809 measured by ELISpot after incubating PBMCs in spike- or RBD-coated plates
 810 for 18 h. Representative ELISpot images were shown. (H, I) Numbers of Spike-
 811 or RBD-specific IgG-secreting B cells per 10⁶ PBMCs were summarized.
 812 Comparisons were done by one-way ANOVA corrected for multiple
 813 comparison in panels B, D and Student's paired-T test in panels H and I.
 814 ***p<0.001, ****p<0.0001; ns, not significant.
 815

Figure 3 Cellular responses induced by a third dose of inactivated SARS-CoV-2 vaccine. (A) PBMCs were stimulated with or without the spike peptide pool (2 μ g/ml). Anti-CD3/CD28 dynabeads served as positive control. IFN γ producing T cells were detected by ELISpot after 24 h incubation. Representative images of ELISpot wells were shown. (B) The number of IFN γ -producing T cells was quantified as the spot-forming units (s.f.u.) per 10^6 PBMCs. (C-G) PBMCs were stimulated with spike peptide pool (2 μ g/ml) for 12 h. Activation-induced markers (AIM) CD69 and 4-1BB were measured by flow cytometry. (C) Representative FACS plots showing the SARS-CoV-2-specific

826 AIM⁺ CD8⁺ T cells. (D) Percentages of AIM⁺ CD8⁺ T cells were summarized. (E)

827 T_N (CD45RA⁺CCR7⁺), T_{EM} (CD45RA⁺CCR7⁻), T_{CM} (CD45RA⁻CCR7⁺), T_{ERMA}

828 (CD45RA⁺CCR7⁻) populations in AIM⁺ CD8⁺ T cells. (F, G)

829 SARS-CoV-2-specific CD3⁺CD4⁻CD8⁻ (DN) T cells were identified by CD69

830 and 4-1BB after spike peptide pool stimulation. (H, I) Intracellular cytokine

831 staining assays were performed to confirm the presence of

832 SARS-CoV-2-specific CD8⁺ T cells in PBMCs by measuring intracellular IFN γ

833 expression after peptide pool stimulation. Comparisons were done by

834 Student's paired-T test in panels B, D and G and one-way ANOVA corrected

835 for multiple comparison in panel I. ****p<0.0001; ns, not significant.

836

Figure 4 Rapid induction of CD4⁺ T cells by the third dose. (A, B)

Activation-induced markers (AIM) OX40 and 4-1BB in CD4⁺ T cells were detected after incubating PBMCs with spike peptide pool (2 µg/ml) for 12 h.

Percentages of AIM⁺ CD4⁺ T cells in the PBMCs were summarized. (C) T_N (CD45RA⁺CCR7⁺), T_{EM} (CD45RA⁻CCR7⁻), T_{CM} (CD45RA⁻CCR7⁺), T_{ERMA} (CD45RA⁺CCR7⁻) populations in AIM⁺ CD4⁺ T cells were gated. (D)

Expression of CXCR5 in AIM⁺ CD4⁺ T cells was measured by flow cytometry.

(E) Percentages of circulating follicular helper T cells (cTFH) in total CD4⁺ T

846 cells were summarized. (F) UMAP plot showed the distribution of cTFH cells
 847 among AIM⁺ CD4⁺ T cells. (G) Percentage of cTFH cells in AIM⁺ CD4⁺ T cells.
 848 (H, I) Intracellular cytokine staining assays were performed to confirm the
 849 presence of SARS-CoV-2-specific CD4⁺ T cells in PBMCs by measuring
 850 intracellular IFN γ expression after peptide pool stimulation. Comparisons were
 851 done by Student's paired-T test in panels B and E and one-way ANOVA
 852 corrected for multiple comparison in panel I. *p<0.05, ***p<0.001,
 853 ****p<0.0001.

854

Figure 5 Immune responses in healthcare workers with minimal serologic response to a standard two-dose vaccination schedule. (A) Serum NABs in HCWs with minimal serologic response to a standard two-dose vaccination schedule were analyzed longitudinally at different time points before and after the third dose (red arrow). (B) Comparison of NABs between

vaccinees with negative or positive serological responses to a standard two-dose vaccination schedule. (C) Percentages of spike-specific memory B cells in HCWs with a negative serological response to a standard two-dose vaccination schedule. (D-F) Numbers of spike- or RBD-specific IgG-producing B cells in HCWs with a negative serological response to a standard two-dose vaccination schedule. (G, H) Numbers of spike-specific IFN γ producing T cells as detected by ELISpot in HCWs with a negative serological response to a standard two-dose vaccination schedule. (I-K) Spike-specific T cells, including CD69⁺4-1BB⁺CD8⁺ T cells, OX40⁺4-1BB⁺CD4⁺ T cells and CXCR5⁺OX40⁺4-1BB⁺ cTFH in HCWs with a negative serological response to a standard two-dose vaccination schedule. Comparisons were done by Wilcoxon rank sum test in B and One-way ANOVA corrected for multiple comparison in the rest panels. *p<0.05, **p<0.01, ****p<0.0001; ns, not significant.